Rituxan With or Without Methotrexate in Psoriatic Arthritis

Part of paid clinical trials in La Jolla, California.

Sponsor
Swedish Medical Center
Study ID
NCT00509678
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.

Study Details

The purpose of this study is to help determine the effectiveness of rituxan (with or without methotrexate) in the treatment of psoriatic arthritis.

Key Dates

Start date
Dec 31, 2006
Status verified
Jan 2012
Primary completion
Jan 31, 2010
Completion
Mar 31, 2010

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Safety of Rituximab in PSA and psoriasis by determining incidence of treatment emergent AE's including infections, infusion reactions and disease progression. [ Time Frame: followed out for one year from last dose ]

Locations (4)

FacilityCityStateZIPSite coordinators
University of California, San DiegoLa JollaCalifornia92037-0943-
Stanford UniversityStanfordCalifornia94305-5350-
University of RochesterRochesterNew York14642-
Swedish Rheumatology ResearchSeattleWashington98104-

Find similar trials in La Jolla, CA

By condition
Psoriatic arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
University of California, San Diego· La Jolla, CAStanford University· Stanford, CAUniversity of Rochester· Rochester, NYSwedish Rheumatology Research· Seattle, WA

Related Studies